Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
CPE CONSULTANTS, LLC
 

Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes (DIaMonD) Trial


Thank you for viewing the cgmEDUCATION.net webcast, successfully passing the PostTest and completing the Evaluation.  In order to claim your continuing education credit you must select Create an Account at the top right of this screen.
 
REMEMBER ALL CONTINUING EDUCATION CREDITS ARE NOW REPORTED ELECTRONICALLY TO CPE MONITOR USING YOUR NABP E-PROFILE NUMBER AND YOUR DATE OF BIRTH.  PLEASE MAKE SURE THESE TWO PIECES OF INFORMATION ARE CORRECTLY ENTERED INTO YOUR ONLINE PROFILE.  INCORRECT DATA WILL RESULT IN REJECTION OF CONTINUING PHARMACY EDUCATION CREDIT BY CPE MONITOR.
 
Please contact the system administrator Anne Hermiller (hermiller50@gmail.com) to report any questions or issues with the reporting of your continuing education credits.

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

CPE Consultants, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
Accreditation Council for Pharmacy Education
 

Requirements for CE Credit

  CPE Consultants LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). The Universal Activity Number (UAN) for this activity is 0864-0000-16-079-H04-P. The activity is accredited for 1.0 contact hour (0.1 CEUs). The official release date for this activity is January 1, 2017 and the expiration date is January 1, 2018.
Statement of ACPE Credit will be provided upon completion of the requirements for this activity (completing the pretest, viewing the webcast and successfully passing the posttest) by the approved provider, CPE Consultants LLC.
Your continuing education credits will be electronically be uploaded to CPE Monitor within 48 hours. Please check your CPE Monitor account to make sure your credits were accurately reported. We encourage participants to keep a printed copy of all statements of continuing education credit.

Support/Credits

Disclosure Policy Statement
It is the policy of CPE Consultants LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. CPE Consultants LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
 
The following faculty members have the following financial relationships with commercial interests:
 
Andrew Ahmann: Consultant/Speaker’s Bureau for: Boehringer Ingelheim; Calibra; Dynavax; Dexcom; Janssen; Merck; and Novo Nordisk
Grant/Research Support from: Dexcom; Lexicon; Metronic; NovoNordisk; and Sanofi-Aventis
and will not discuss off label use and/or investigational use in this presentation.
 
Janet McGill, Consultant for: Dexcom; Horizon CME and Novo Nordisk Speaker’s Bureau for: Horizon CME
Grant/Research Support from: BMS-AZ; Dexcom; Lexicon; and Novartis
and will not discuss off label use and/or investigational use in this presentation.
 
CPE Consultants, LLC Disclosure
Anne Hermiller and John Stanovich, RPh have no real or apparent conflicts of interest to report.

 

 

 

Define the role of CGM in diabetes management treatment decisions for intensive insulin therapy patients
Employ novel management strategies in personal and professional RT-COM
Identify patient types via clinical case reports that will most benefit from RT-CGM

Speaker(s)/Author(s)

Andrew Ahmann , MD
Professor of Medicine, Oregon Health and Science University


Brief Bio : Dr. Andrew Ahmann is Professor of Medicine and the Director of the Oregon Health and Science University (OHSU) Harold Schnitzer Diabetes Health Center at OHSU. He has been chair of the Oregon Diabetes Guidelines Committee and the Oregon Diabetes Collaborative Program. He volunteers in many capacities for diabetes causes regional and nationally. He served on the ADA Professional Practice Committee. He serves on committees for the Endocrine Society and AACE. He is President of The Portland Area Leadership board of the ADA. He is active in patient care, teaching, and clinical research.
Disclosure : I have the following financial relationships to disclose: Consultant/Speaker’s Bureau for: Boehringer Ingelheim; Calibra; Dynavax; Dexcom; Janssen; Merck; and Novo Nordisk Grant/Research Support from: Dexcom; Lexicon; Metronic; NovoNordisk; and Sanofi-Aventis and I will not discuss off label use and/or investigational use in my presentation.

Janet B. McGill, MD, MA, FACE
Professor of Medicine, Washington University School of Medicine


Brief Bio : Dr. Janet McGill is Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine in St. Louis, Missouri, and attending physician at Barnes-Jewish Hospital in St. Louis. She directed the fellowship in Endocrinology, Diabetes and Metabolism at Washington University from 2009 – 2016. Dr. McGill is nationally and internationally known for her work in clinical and translational research in Type 1 and Type 2 diabetes and diabetes complications. She has been the principal investigator and co-investigator or sub-investigator on over 200 clinical trials in diabetes, hypertension, hyperlipidemia, diabetic nephropathy, diabetic neuropathy and diabetes related devices. In addition to serving on steering and safety committees for international multi-centered clinical trials, she has been the lead investigator on sponsored studies and has served on DSMBs on short and long-term outcome studies. She is the PI of the GRADE and PERL studies at Washington University. Dr. McGill has published over 150 peer-reviewed articles, numerous commentaries and editorials, and 18 chapters, and she has edited two books. She has been on the editorial boards of several journals and has lectured nationally and internationally on diabetes and related topics. She is a member of the board of directors of AACE, and serves on several scientific and planning committees, and is active in the Endocrine Society and ADA. Dr. McGill graduated from the University of Michigan (bachelors), Northern Michigan University (master’s) and Michigan State College of Human Medicine. She was an intern, resident and chief resident at William Beaumont Hospital in Royal Oak, Michigan.
Disclosure : I have the following financial relationships to disclose: Consultant for: Dexcom; Horizon CME and Novo Nordisk Speaker’s Bureau for: Horizon CME Grant/Research Support from: BMS-AZ; Dexcom; Lexicon; and Novartis and I will not discuss off label use and/or investigational use in my presentation.

Activity Number

0864-0000-16-079-H04-P

Release Date: Jan 1, 2017
Credit Expiration Date: Jan 1, 2018